IW-601

IW-601 is a proprietary, first-in-class monoclonal antibody developed by ImmuneWalk Therapeutics. It is engineered to specifically target MOSPD2, an adhesion checkpoint protein expressed on the surface of myeloid cells (notably monocytes and neutrophils). By binding to MOSPD2, IW-601 prevents these immune cells from migrating into inflamed tissues, thereby reducing immune-driven inflammation without depleting blood cells. This mechanism offers a differentiated approach compared to traditional anti-inflammatory therapies. Preclinical studies have demonstrated disease-modifying activity in models of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease (IBD), metabolic dysfunction-associated steatohepatitis (MASH; formerly NASH), and uveitis. The drug is currently being evaluated in the POINTGUARD Phase 1 clinical trial for safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers[1][2][3][4][9].